HUTCHMED (China) analyst ratings
HUTCHMED (China) analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2022 | 14.86% | Goldman Sachs | $14 → $16 | Maintains | Neutral |
| 08/02/2022 | 0.5% | Goldman Sachs | $16 → $14 | Maintains | Neutral |
| 09/22/2021 | 230.22% | Goldman Sachs | → $46 | Downgrades | Buy → Neutral |
| 08/03/2021 | 273.3% | Jefferies | → $52 | Initiates Coverage On | → Buy |
| 03/13/2020 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
| 02/20/2020 | 172.79% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
| 11/19/2019 | — | CLSA | Initiates Coverage On | → Buy | |
| 10/23/2019 | — | B of A Securities | Reinstates | → Buy | |
| 03/04/2019 | — | Deutsche Bank | Initiates Coverage On | → Buy | |
| 10/17/2017 | 172.79% | Canaccord Genuity | $30 → $38 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2022 | 14.86% | 高盛 | $14 → $16 | 維護 | 中性 |
| 08/02/2022 | 0.5% | 高盛 | $16 → $14 | 維護 | 中性 |
| 09/22/2021 | 230.22% | 高盛 | → $46 | 評級下調 | 購買→中性 |
| 08/03/2021 | 273.3% | 傑富瑞 | → $52 | 開始承保 | →購買 |
| 03/13/2020 | — | 康託·菲茨傑拉德 | 開始承保 | →超重 | |
| 02/20/2020 | 172.79% | 高盛 | → $38 | 開始承保 | →購買 |
| 11/19/2019 | — | 里昂證券 | 開始承保 | →購買 | |
| 10/23/2019 | — | B of A證券 | 恢復 | →購買 | |
| 03/04/2019 | — | 德意志銀行 | 開始承保 | →購買 | |
| 10/17/2017 | 172.79% | 卡納科特·格納奇 | $30 → $38 | 維護 | 買 |
HUTCHMED (China) Questions & Answers
和黃醫藥(中國)問答
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Goldman Sachs on August 9, 2022. The analyst firm set a price target for $16.00 expecting HCM to rise to within 12 months (a possible 14.86% upside). 3 analyst firms have reported ratings in the last year.
高盛於2022年8月9日報告了和黃醫藥(中國)(納斯達克代碼：HCM)的最新目標價。這家分析公司將目標價定為16.00美元，預計HCM將在12個月內上漲(可能上漲14.86%)。3家分析公司在過去一年公佈了評級。
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Goldman Sachs, and HUTCHMED (China) maintained their neutral rating.
高盛提供對和黃醫藥(中國)(納斯達克代碼：HCM)的最新分析師評級，和黃醫藥(中國)維持中性評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on August 9, 2022 so you should expect the next rating to be made available sometime around August 9, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閲公開財務報表，與和黃醫藥(中國)的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。和黃醫藥(中國)的上一次評級是在2022年8月9日提交的，所以你應該預計下一次評級將在2023年8月9日左右公佈。
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a maintained with a price target of $14.00 to $16.00. The current price HUTCHMED (China) (HCM) is trading at is $13.93, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的和黃醫藥(中國)(HCM)評級維持不變，目標價在14.00美元至16.00美元之間。和黃醫藥(中國)目前的股價為13.93美元，超出了分析師的預測區間。